Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 1Anemia 1

Interventions

Specimen Handling 277Magnetic Resonance Spectroscopy 228pembrolizumab 227Carboplatin 177Biopsy 168Cisplatin 164Nivolumab 157Cyclophosphamide 143Paclitaxel 123Radiotherapy 122Gemcitabine 115Bevacizumab 94durvalumab 91Dexamethasone 87Rituximab 79Oxaliplatin 78venetoclax 73atezolizumab 72Docetaxel 69Capecitabine 69Fluorouracil 68Doxorubicin 67Etoposide 65Radiosurgery 62Ipilimumab 61Prednisone 60Cytarabine 60Radiation 59Lenalidomide 56Pemetrexed 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × luspatercept × 90 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡